Source:http://linkedlifedata.com/resource/pubmed/id/20010625
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-2-10
|
| pubmed:abstractText |
Between 1981 and 2000, 6609 children (<18 years of age) were treated in five consecutive trials of the Berlin-Frankfurt-Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). Patients were treated in up to 82 centers in Germany, Austria and Switzerland. Probability of 10-year event-free survival (EFS) (survival) improved from 65% (77%) in study ALL-BFM 81 to 78% (85%) in ALL-BFM 95. In parallel to relapse reduction, major efforts focused on reducing acute and late toxicity through advanced risk adaptation of treatment. The major findings derived from these ALL-BFM trials were as follows: (1) preventive cranial radiotherapy could be safely reduced to 12 Gy in T-ALL and high-risk (HR) ALL patients, and eliminated in non- HR non-T-ALL patients, if it was replaced by high-dose and intrathecal (IT) MTX; (2) omission of delayed re-intensification severely impaired outcome of low-risk patients; (3) 6-month-less maintenance therapy caused an increase in systemic relapses; (4) slow response to an initial 7-day prednisone window was identified as adverse prognostic factor; (5) condensed induction therapy resulted in significant improvement of outcome; (6) the daunorubicin dose in induction could be safely reduced in low-risk patients and (7) intensification of consolidation/re-intensification treatment led to considerable improvement of outcome in HR patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1476-5551
|
| pubmed:author |
pubmed-author:GadnerHH,
pubmed-author:HarbottJJ,
pubmed-author:HenzeGG,
pubmed-author:KlingebielTT,
pubmed-author:KremensBB,
pubmed-author:LudwigW DWD,
pubmed-author:MörickeAA,
pubmed-author:MannGG,
pubmed-author:NiemeyerCC,
pubmed-author:NiethammerDD,
pubmed-author:NiggliFF,
pubmed-author:OdenwaldEE,
pubmed-author:ReiterAA,
pubmed-author:RiehmHH,
pubmed-author:RitterJJ,
pubmed-author:SchrappeMM,
pubmed-author:SchrauderAA,
pubmed-author:StanullaMM,
pubmed-author:WelteKK,
pubmed-author:ZimmermannMM,
pubmed-author:ZintlFF
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
24
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
265-84
|
| pubmed:meshHeading |
pubmed-meshheading:20010625-Adolescent,
pubmed-meshheading:20010625-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20010625-Child,
pubmed-meshheading:20010625-Child, Preschool,
pubmed-meshheading:20010625-Combined Modality Therapy,
pubmed-meshheading:20010625-Cranial Irradiation,
pubmed-meshheading:20010625-Female,
pubmed-meshheading:20010625-Follow-Up Studies,
pubmed-meshheading:20010625-Humans,
pubmed-meshheading:20010625-Immunophenotyping,
pubmed-meshheading:20010625-Infant,
pubmed-meshheading:20010625-Male,
pubmed-meshheading:20010625-Neoplasm Recurrence, Local,
pubmed-meshheading:20010625-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:20010625-Prognosis,
pubmed-meshheading:20010625-Risk Factors,
pubmed-meshheading:20010625-Stem Cell Transplantation,
pubmed-meshheading:20010625-Survival Rate,
pubmed-meshheading:20010625-Time Factors,
pubmed-meshheading:20010625-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
|
| pubmed:affiliation |
Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|